By physician referral or invitation only

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis

This study aims to evaluate the efficacy and safety of the drug: NMD670 in adults who have Myasthenia Gravis.

Age & Gender

18 years ~ 75 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

James Howard
Neurology-Neuromuscular

Study Type

Clinical or Medical
Interventional

Study Topics

Chronic Conditions

IRB Number

24-0825

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.